Health
New study from MD Anderson and BridgeBio’s Navire Pharma shows SHP2 inhibition overcomes multiple – Mirage News
New preclinical research from The University of Texas MD Anderson Cancer Center and BridgeBio Pharma, Inc. affiliate Navire Pharma, Inc., finds that the…
New preclinical research from The University of Texas MD Anderson Cancer Center and BridgeBio Pharma, Inc. affiliate Navire Pharma, Inc., finds that the novel SHP2 inhibitor IACS-13909 is able to overcome multiple therapeutic-resistance mechanisms in non-small cell lung cancer (NSCLC), suggesting a possible new approach to treating cancers that have developed resistance to the targeted EGFR inhibitor osimertinib.
The data is published today in Cancer Research, a journal of the American Associat…
-
Noosa News19 hours agoSuncorp Stadium upgrades to rival Sydney as seat capacity and infrastructure prioritised
-
General12 hours agoAustralia Kangaroos lose Xavier Coates and Zac Lomax ahead of rugby league Ashes in England
-
Business21 hours agoDroneShield announces new $13 million counter-drone facility as employees top 400
-
Business22 hours agoWhy you should sell CBA, Lynas, and Tabcorp shares today